Skip to Main Content

Author Details

Mark C Gillies
The University of Sydney Save Sight Institute
1987
319
53
PMIDPaper TitleJournal TitlePublished Year
34340975Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.Br J Ophthalmol2023
37956321Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy.Ophthalmic Surg Lasers Imaging Retina2023
37898362From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema.Prog Retin Eye Res2023
37505396Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.Ophthalmol Ther2023
37871984Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians.Clin Exp Ophthalmol2023
35508721Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.Eye (Lond)2023
37315899Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases.Adv Drug Deliv Rev2023
37246495Opportunities and challenges for clinical registries.Clin Exp Ophthalmol2023
37371607The Role of Nrf2/sMAF Signalling in Retina Ageing and Retinal Diseases.Biomedicines2023
37069239Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO).Eye (Lond)2023
36536538Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5â¿¿years of follow-up from Fight Retinal Blindness registry.Acta Ophthalmol2023
36893432OUTCOMES OF SWITCHING FROM PROACTIVE TO REACTIVE TREATMENT AFTER DEVELOPING ADVANCED CENTRAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2023
36371040Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.Ophthalmol Retina2023
35140329Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration.Eye (Lond)2023
35078771Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.Br J Ophthalmol2023
33196150Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry.Acta Ophthalmol2022
35760858Author Correction: Neuroimaging and cognitive correlates of retinal Optical Coherence Tomography (OCT) measures at late middle age in a twin sample.Sci Rep2022
35624805Metabolism Dysregulation in Retinal Diseases and Related Therapies.Antioxidants (Basel)2022
35688899Neuroimaging and cognitive correlates of retinal Optical Coherence Tomography (OCT) measures at late middle age in a twin sample.Sci Rep2022
35779441Transketolase in human Müller cells is critical to resist light stress through the pentose phosphate and NRF2 pathways.Redox Biol2022
35589075Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.Ophthalmol Retina2022
35869925One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion.Clin Exp Ophthalmol2022
36241963Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis.Adv Ther2022
33767407Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry.Eye (Lond)2022
33712484Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.Br J Ophthalmol2022
35188495IMPAIRMENTS IN CONE PIGMENT REGENERATION AND ABSOLUTE THRESHOLD IN MACULAR TELANGIECTASIA TYPE 2.Retina2022
35179714Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry.Ophthalmol Ther2022
35307607Characterization of Poor Visual Outcomes of Diabetic Macular Edema: The Fight Retinal Blindness! Project.Ophthalmol Retina2022
34907129INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES: Fight Retinal Blindness Registry.Retina2022
35174799THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.Retina2022
35106882Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.Clin Exp Ophthalmol2022
35080803Quality of life impact of eye diseases: a Save Sight Registries study.Clin Exp Ophthalmol2022
35322568Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry.Acta Ophthalmol2022
3451916712-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.Acta Ophthalmol2022
33960115Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.Acta Ophthalmol2022
34292225THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Retina2022
32310628FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project.Retina2021
33881205Effect of intravitreal injection speed on acute rise in intraocular pressure. The SPEED IOP study.Clin Exp Ophthalmol2021
33560780SURGICAL RETINAL EXPLANTS AS A SOURCE OF RETINAL PROGENITOR CELLS.Retina2021
33835598Effect of selectively knocking down key metabolic genes in Müller glia on photoreceptor health.Glia2021
34730771Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis.Transl Vis Sci Technol2021
34722826Isolation, Culture, and Identification of Primary Muller Cells from Human Retina.Bio Protoc2021
34796271Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry.BMJ Open Ophthalmol2021
34129283Neovascular age-related macular degeneration at treatment intervals of 14â¿¿weeks or greater.Clin Exp Ophthalmol2021
34013534Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry.Clin Exp Ophthalmol2021
34011714Vitreoretinal Society of India practice pattern survey 2020: Medical retina.Indian J Ophthalmol2021
34058152Outer Retinal Layer Thickening Predicts the Onset of Exudative Neovascular Age-Related Macular Degeneration.Am J Ophthalmol2021
33219442Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.Graefes Arch Clin Exp Ophthalmol2021
33332811ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR.Retina2021
33239765Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence.Eye (Lond)2021
  • 1 - 50 of 319

Recommended Authors

Vaidehi S Dedania
Department of Ophthalmology at NYU Grossman School of Medicine
Career Start Year 2015
Number of shared co-authors 2
Konstantinos Balaskas
University of Manchester
Career Start Year 2009
Number of shared co-authors 24
Roy Schwartz
Moorfields Eye Hospital NHS Foundation Trust
Career Start Year 2006
Number of shared co-authors 16
Caio V Regatieri
Universidade Federal de Sao Paulo
Career Start Year 2006
Number of shared co-authors 2
Adam R Glassman
Jaeb Center for Health Research
Career Start Year 2006
Number of shared co-authors 5
Katherine E Talcott
Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic
Career Start Year 2005
Number of shared co-authors 1
Richard Gale
Hull York Medical School, University of York
Career Start Year 2003
Number of shared co-authors 22
Jayashree Sahni
Novartis Pharma AG
Career Start Year 2001
Number of shared co-authors 9
Sajjad Mahmood
University of Manchester
Career Start Year 2001
Number of shared co-authors 10
Rishi P Singh
Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida
Career Start Year 2000
Number of shared co-authors 9
Igor Kozak
Moorfields Eye Hospital Dubai.
Career Start Year 1999
Number of shared co-authors 18
Robin Hamilton
Moorfields Eye Hospital NHS Foundation Trust
Career Start Year 1998
Number of shared co-authors 17
Yasuo Yanagi
Yokohama City University Medical Center
Career Start Year 1998
Number of shared co-authors 7
Glenn Yiu
University of California davis
Career Start Year 1998
Number of shared co-authors 5
Clare Bailey
Bristol Eye Hospital
Career Start Year 1997
Number of shared co-authors 18
Andrew J Lotery
University of Southampton
Career Start Year 1994
Number of shared co-authors 35
Rajendra S Apte
Washington University School of Medicine
Career Start Year 1994
Number of shared co-authors 6
Judy E Kim
Medical College of Wisconsin
Career Start Year 1994
Number of shared co-authors 11
Timothy W Olsen
Mayo Clinic
Career Start Year 1993
Number of shared co-authors 3
Stephen J Talks
Newcastle Hospitals NHS Foundation Trust
Career Start Year 1993
Number of shared co-authors 19
Allen C Ho
Wills Eye Hospital/Mid Atlantic Retina
Career Start Year 1992
Number of shared co-authors 6
Faruque Ghanchi
Bradford Teaching Hospitals NHS Foundation Trust
Career Start Year 1992
Number of shared co-authors 12
Joan W Miller
Harvard Medical School
Career Start Year 1989
Number of shared co-authors 8
Michael W Stewart
Mayo Clinic
Career Start Year 1988
Number of shared co-authors 7
Jennifer I Lim
University of Illinois at Chicago
Career Start Year 1986
Number of shared co-authors 9
Lloyd Paul Aiello
Joslin Diabetes Center, Beetham Eye Institute
Career Start Year 1986
Number of shared co-authors 13
Ronald P Danis
University of Wisconsin, Wisconsin EyeKor Inc.
Career Start Year 1981
Number of shared co-authors 14
Neil M Bressler
Wilmer Eye Institute, Johns Hopkins University School of Medicine
Career Start Year 1979
Number of shared co-authors 19
Maureen G Maguire
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1979
Number of shared co-authors 8
Frederick L Ferris
National Eye Institute, National Institutes of Health
Career Start Year 1962
Number of shared co-authors 14

Collaborators

Daniel Barthelmes
University Hospital Zurich and University of Zurich
Co-authored papers 85
Vuong Nguyen
The University of Sydney Save Sight Institute
Co-authored papers 79
Hemal Mehta
The University of Sydney Save Sight Institute
Co-authored papers 34
Ian L McAllister
University of Western Australia, Lions Eye Institute
Co-authored papers 33
Robyn H Guymer
Royal Victorian Eye and Ear Hospital, the University of Melbourne
Co-authored papers 25
Vincent Daien
University Hospital Montpellier
Co-authored papers 21
Chui Ming Gemmy Cheung
Singapore Eye Research Institute
Co-authored papers 12
Tien Yin Wong
Tsinghua University
Co-authored papers 11
Jamie E Craig
Flinders Medical Centre, Flinders University
Co-authored papers 10
Javier Zarranz-Ventura
Hospital Clinic of Barcelona, University of Barcelona
Co-authored papers 9
Emily Y Chew
National Eye Institute, National Institutes of Health
Co-authored papers 9
Marcus Fruttiger
UCL Institute of Ophthalmology
Co-authored papers 9
Ecosse L Lamoureux
Singapore Eye Research Institute
Co-authored papers 8
Nikolai Petrovsky
Co-authored papers 8
Tunde Peto
Queen's University Belfast
Co-authored papers 8
Alex W Hewitt
Menzies Institute for Medical Research, University of Tasmania
Co-authored papers 8
Kelvin Yi Chong Teo
Singapore Eye Research Institute
Co-authored papers 8
Traci E Clemons
The EMMES Corporation
Co-authored papers 7
Peter McCluskey
Save Sight Institute, University of Sydney
Co-authored papers 5
Frank G Holz
University of Bonn
Co-authored papers 5
Catherine Egan
Moorfields Eye Hospital NHS Foundation Trust
Co-authored papers 5
Peter Charbel Issa
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust
Co-authored papers 4
Martin Friedlander
the Scripps Research Institute
Co-authored papers 3
Gerald Liew
Westmead Clinical School, University of Sydney
Co-authored papers 3
Robert P Finger
Universitats-Augenklinik Mannheim
Co-authored papers 3
Ningli Wang
Beijing Tongren Hospital, Capital Medical University
Co-authored papers 3
Rando Allikmets
Columbia University Medical Center
Co-authored papers 3
Adnan Tufail
Moorfields Eye Hospital NHS Foundation Trust
Co-authored papers 3
Paul S Bernstein
University of Utah
Co-authored papers 3
Hendrik P N Scholl
Institute of Molecular and Clinical Ophthalmology Basel
Co-authored papers 3
Release 1.2